Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report

At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose. The literature on the treatment of recurrent glioblastoma (GBM) by conventionally fractionated stereotactic radiotherapy (CFRT) is even rarer. A 44-ye...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2019-01, Vol.98 (1), p.e13869-e13869
Main Authors: Qie, Shuai, Yuan, Lanhui, Shi, Hong-Yun, Zhang, Xi, Li, Yanhong
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents, Alkylating - therapeutic use
Brain Neoplasms - therapy
Clinical Case Report
Combined Modality Therapy
Female
Glioblastoma - therapy
Humans
Neoplasm Grading
Neoplasm Recurrence, Local
Radiation Dosage
Radiosurgery - methods
Reoperation - methods
Temozolomide - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose. The literature on the treatment of recurrent glioblastoma (GBM) by conventionally fractionated stereotactic radiotherapy (CFRT) is even rarer. A 44-year-old woman was admitted to our hospital for residual tumor after reoperation. Postoperative pathological diagnosis was GBM, WHO grade IV. The brain magnetic resonance imaging re-examination showed abnormal enhancement around the local operative region after resection of the left frontal lobe tumor, and there was presence of residual tumor. The patient was treated with reoperation followed by re-irradiation plus dose-dense TMZ to achieve complete remission. Complete remission was observed at the end of radiotherapy and at the 1 month follow-up after radiotherapy. This study suggests that CFRT plus dose-dense TMZ might be a feasible option for the treatment in relapsed malignant glioma patients with good general condition.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000013869